November 18, 2026

What the FDA’s New Potency Assurance Guidance Means for Cell Therapy Developers, Gene Therapy Manufacturers, Biotech Companies and Biologics License Applicants

The US Food and Drug Administration (FDA) has issued its final guidance, Potency Assurance for Cellular and Gene Therapy Products, in November 2026, introducing comprehensive recommendations for establishing a science- and risk-based approach to ensuring the potency of cellular and gene therapy (CGT) products.

Issued by the FDA's Center for Biologics Evaluation and Research (CBER), the guidance supersedes the January 2011 guidance, Potency Tests for Cellular and Gene Therapy Products. It introduces a broader approach that integrates manufacturing process design, material controls, in-process testing, potency assays and quality risk management throughout the product lifecycle.

The guidance aims to help manufacturers ensure that every released product lot has the specific ability or capacity to achieve its intended therapeutic effect.

The recommendations apply to human cellular and gene therapy products regulated as biological products under Section 351 of the Public Health Service Act (PHS Act). They cover potency assurance during product development, clinical investigations, biologics license applications (BLAs) and commercial manufacturing.

For biotechnology companies, the updated guidance highlights the importance of understanding product mechanisms of action, identifying potency-related critical quality attributes (CQAs), establishing reliable analytical methods and maintaining consistent manufacturing controls.

Companies developing advanced therapies should review their existing chemistry, manufacturing and controls (CMC) strategies to identify gaps and align potency assurance activities with FDA's latest recommendations.

Why FDA's New CGT Potency Assurance Guidance Matters

Cellular and gene therapies are complex biological products whose therapeutic activity can be influenced by starting material variability, manufacturing conditions, storage, transportation and administration.

Unlike conventional pharmaceuticals, many CGT products involve living cells, genetically modified materials or biological components that may demonstrate significant variability between manufacturing batches.

Consequently, potency cannot always be adequately demonstrated through a single laboratory test performed at the end of manufacturing.

The FDA's November 2026 guidance emphasizes a comprehensive potency assurance strategy that integrates multiple controls rather than relying exclusively on final product release testing.

The guidance is particularly important for:

  • Cell and gene therapy manufacturers.
  • Biotechnology and pharmaceutical companies.
  • Advanced therapy medicinal product developers.
  • Contract development and manufacturing organizations (CDMOs).
  • Clinical-stage biotechnology companies.
  • Biologics license applicants.
  • Quality assurance and quality control teams.
  • Analytical development and CMC professionals.
  • Regulatory affairs and manufacturing compliance teams.

Businesses may need to strengthen their existing systems across product characterization, raw material qualification, manufacturing process validation, analytical method development and lifecycle management.

What Is FDA's Potency Assurance Guidance for Cellular and Gene Therapy Products?

The final guidance provides recommendations for developing and implementing a comprehensive strategy to assure the potency of human cellular and gene therapy products.

It establishes a framework based on five interconnected elements:

  1. Manufacturing process design.
  2. Manufacturing process control.
  3. Material control.
  4. In-process testing.
  5. Potency lot-release assays.

The guidance also explains how manufacturers should progressively develop their potency assurance strategies as products advance through clinical development and commercialization.

Unlike the January 2011 guidance, which primarily focused on potency testing, the November 2026 final guidance provides a broader framework integrating potency assurance into existing quality management and manufacturing systems.

Regulatory Background and Important Details

Regulatory Element

Details

Regulatory Authority

US Food and Drug Administration (FDA)

Responsible Centre

Center for Biologics Evaluation and Research (CBER)

Guidance Title

Potency Assurance for Cellular and Gene Therapy Products

Final Guidance Date

November 2026

Federal Register Publication

3 November 2026

Docket Number

FDA-2023-D-4299

Previous Guidance

January 2011 Potency Tests for Cellular and Gene Therapy Products

Regulatory Framework

Section 351 of the Public Health Service Act

Primary Focus

Science- and risk-based CGT potency assurance

Applicable Lifecycle Stages

Product development, clinical investigations and commercial manufacturing

The guidance supersedes the January 2011 document and provides recommendations for integrating potency assurance into existing quality systems.

Important regulatory distinction: FDA guidance documents generally contain non-binding recommendations rather than independently enforceable requirements. However, applicable statutory and regulatory requirements, including potency testing obligations for licensed biological products, remain binding.

Scope of Application and Regulatory Framework

The guidance applies to human cellular therapy and gene therapy products regulated as biological products under Section 351 of the PHS Act.

It includes tissue-engineered medical products regulated under the same statutory framework.

The recommendations address potency assurance across different stages of product development and commercialization.

The guidance does not apply to:

  • Vaccines for infectious disease indications.
  • Bacteriophage products.
  • Live biotherapeutic products.
  • Faesal microbiota transplantation (FMT) products.
  • Allergenic products.

Licensed and Investigational CGT Products

The FDA distinguishes between licensed products and investigational products when discussing potency assurance.

For licensed products, each lot must undergo potency testing using samples collected after completion of all manufacturing steps that may affect potency.

For investigational products, potency assurance should progressively improve according to the clinical development phase. The level of control and supporting documentation should reflect the product's development stage and associated risks.

Manufacturers must also maintain appropriate current Good Manufacturing Practice (CGMP) controls throughout manufacturing.

Developing a Science- and Risk-Based Potency Assurance Strategy

One of the central recommendations in the final guidance is to establish a comprehensive potency assurance strategy using quality risk management principles.

The objective is to identify factors that may adversely affect product potency and establish appropriate controls to minimize those risks.

1. Product and Process Understanding

Manufacturers should develop a thorough understanding of the product's mechanism of action (MOA), intended therapeutic effect and manufacturing process.

This includes identifying:

  • Potency-related critical quality attributes (CQAs).
  • Critical process parameters (CPPs).
  • Relevant starting material characteristics.
  • Product-specific biological activities.
  • Manufacturing variables affecting potency.
  • Potential changes during storage and handling.

The relationship between product characteristics and therapeutic activity should guide the development of suitable potency assays.

2. Quality Risk Assessment

Companies should identify, analyses and evaluate factors that may affect potency throughout manufacturing and product handling.

Risk assessments should consider the probability and severity of potential impacts and, where appropriate, their detectability.

Potential risk areas include:

  • Variability in raw materials.
  • Changes in manufacturing conditions.
  • Inadequate process controls.
  • Storage and transportation conditions.
  • Product handling and preparation.
  • Delivery device compatibility.
  • Changes in potency-related product attributes.

3. Manufacturing Process Design

Manufacturing processes should be designed to consistently produce products with the required potency characteristics.

Companies should establish appropriate controls for starting materials, manufacturing operations, process parameters and product-contact materials.

4. Control Strategy

The control strategy should integrate material testing, process controls, in-process monitoring and potency lot-release testing.

The objective is to ensure that identified potency-related CQAs remain within appropriate predetermined limits.

5. Lifecycle Improvement

Potency assurance should evolve as manufacturers gain additional product knowledge, manufacturing experience and clinical data.

Risk assessments, specifications, analytical methods and manufacturing controls should be reassessed when relevant new information becomes available.

Potency Assays and Testing Requirements

Potency assays are essential components of the overall potency assurance strategy.

However, the FDA emphasizes that release testing alone may not adequately assure product potency.

Manufacturers should select assays that measure relevant potency-related CQAs and address identified risks.

For most CGT products, lot-release testing should include at least one phase-appropriate bioassay measuring biological activity related to the intended therapeutic effect.

Assays should demonstrate suitable performance characteristics, including accuracy, precision, specificity and robustness, as appropriate for their intended use.

Multiple assays may be necessary when a single analytical method cannot adequately evaluate all relevant potency-related attributes.

Key Potency Testing Considerations

Testing Area

FDA Recommendation

Compliance Consideration

Bioassay Development

Include at least one phase-appropriate bioassay for most CGT products

Demonstrate relevant biological activity

Assay Performance

Establish suitable accuracy, precision, specificity and robustness

Ensure reliable analytical results

In-Process Testing

Monitor relevant potency-related attributes during manufacturing

Identify process-related changes

Stability Testing

Evaluate potency-related attributes during storage

Establish appropriate shelf-life support

In-Use Studies

Assess potency during product preparation and administration

Confirm product performance under intended conditions

Comparability Studies

Evaluate potency following manufacturing changes

Demonstrate that changes do not adversely affect potency

Animal-Based Assays

Encourage replacement, reduction or refinement of animal use

Use suitable in-vitro bioassays where feasible

The guidance encourages manufacturers to use in-vitro bioassays instead of animal-based bioassays when this can be achieved without compromising potency assurance.

This approach supports the development of scientifically appropriate and reliable analytical testing strategies.

Progressive Implementation Throughout Product Development

The FDA recommends that potency assurance strategies develop progressively as CGT products advance through clinical investigations.

Early-stage products may initially have limited manufacturing and clinical data. However, manufacturers should strengthen their understanding of the product and improve analytical controls as development progresses.

1.Early Development

During early development, manufacturers should:

  • Identify preliminary potency-related CQAs.
  • Establish an initial understanding of the MOA.
  • Conduct product characterization studies.
  • Perform preliminary risk assessments.
  • Develop initial potency assays.
  • Identify potential manufacturing-related risks.

2. Clinical Development

As products advance through clinical investigations, companies should refine their manufacturing processes, assay performance and control strategies.

Manufacturers should also establish appropriate acceptance criteria and generate supporting data to demonstrate product consistency.

3. Before BLA Submission

Before submitting a BLA, manufacturers should:

  • Reassess the potency assurance strategy using available product and clinical data.
  • Validate assays used for lot-release and in-process testing.
  • Establish appropriate reference materials.
  • Justify potency specifications and acceptance criteria.
  • Document differences between clinical-stage and commercial assays.
  • Demonstrate appropriate control of potency-related attributes.

For products undergoing rapid clinical development, the FDA recommends early product and process characterization and timely development, qualification and implementation of potency assays.

4. Assay Control, Reference Materials and Acceptance Criteria

The final guidance highlights the importance of maintaining reliable potency assays throughout the product lifecycle.

Manufacturers should establish predefined sample suitability and system suitability criteria to identify conditions that may affect assay performance.

Reference materials should also be appropriately qualified and monitored for stability.

Where an assay is modified or transferred between laboratories, manufacturers should conduct appropriate risk assessments and determine whether partial or full revalidation is necessary.

Assay Management and Acceptance Criteria

Compliance Element

Regulatory Recommendation

Expected Documentation

Sample and System Suitability

Establish predefined suitability criteria

Assay protocols and system checks

Reference Materials

Qualify reference materials and monitor stability

Reference material qualification records

Assay Qualification

Demonstrate fitness for intended use

Qualification reports

Assay Validation

Validate assays used for licensed product release

Validation reports

Assay Changes

Assess the need for partial or full revalidation

Change control and risk assessments

Laboratory Transfers

Conduct risk-based assay transfer studies

Transfer protocols and reports

Acceptance Criteria

Establish quantitative potency limits

Approved product specifications

Potency specifications should include quantitative acceptance criteria.

A lower acceptance limit should demonstrate that each lot has adequate biological activity to achieve the intended therapeutic effect.

Where excessive biological activity could create safety concerns, manufacturers should also establish an appropriate upper acceptance limit.

Acceptance criteria should be refined as manufacturing experience and product knowledge increase.

Key Business and Operational Implications

For CGT Manufacturers

  • Strengthen manufacturing process understanding.
  • Identify potency-related CQAs and CPPs.
  • Improve starting material controls.
  • Establish appropriate in-process testing.
  • Review lot-release testing strategies.

For Biotechnology Companies

  • Integrate potency assurance into early product development.
  • Improve product characterization.
  • Develop phase-appropriate potency assays.
  • Strengthen CMC documentation.

For CDMOs

  • Review manufacturing process controls.
  • Maintain qualified analytical methods.
  • Assess laboratory-to-laboratory assay transfers.
  • Support comparability assessments following process changes.

For Regulatory Affairs Teams

  • Review IND and BLA potency documentation.
  • Evaluate alignment with FDA recommendations.
  • Prepare scientific justifications for assay selection.
  • Coordinate early regulatory discussions with CBER where appropriate.

Frequently Asked Questions

1. What is FDA's Potency Assurance for Cellular and Gene Therapy Products guidance?

It is a November 2026 final guidance providing recommendations for developing a science- and risk-based strategy to assure the potency of human cellular and gene therapy products throughout their lifecycle.

2. Does the 2026 guidance replace the previous FDA potency testing guidance?

Yes. The November 2026 final guidance supersedes the January 2011 guidance, Potency Tests for Cellular and Gene Therapy Products.

3. Which products are covered by the guidance?

It covers human cellular and gene therapy products regulated as biological products under Section 351 of the Public Health Service Act, including relevant tissue-engineered medical products.

4. Does the guidance apply to vaccines?

It does not apply to vaccines for infectious disease indications, bacteriophage products, live biotherapeutic products, FMT products or allergenic products.

5. What are the main elements of a potency assurance strategy?

The strategy includes manufacturing process design, manufacturing process control, material control, in-process testing and potency lot-release assays.

6. Are potency assays mandatory for every CGT product?

The applicable regulatory requirements depend on product status and development stage. Each lot of a licensed biological product must undergo potency testing. The guidance recommends phase-appropriate assay strategies for investigational products.

7. Does the FDA recommend bioassays?

Yes. For most CGT products, FDA recommends including at least one phase-appropriate bioassay in lot-release testing to measure biological activity related to the intended therapeutic effect.

8. How should manufacturers establish potency acceptance criteria?

Manufacturers should establish quantitative criteria based on quality risk management, product knowledge and manufacturing experience. Appropriate lower and, where necessary, upper potency limits should be considered.

9. Are animal-based potency assays still acceptable?

The FDA encourages replacement, reduction or refinement of animal use and recommends in-vitro bioassays instead of animal-based bioassays where feasible without compromising potency assurance.

10. What should companies do before BLA submission?

Companies should validate lot-release and in-process assays, establish suitable reference materials, refine acceptance criteria and provide a scientifically justified potency assurance strategy supported by manufacturing and clinical data.

Conclusion

The FDA's November 2026 final guidance on Potency Assurance for Cellular and Gene Therapy Products represents an important development in the regulatory framework for advanced biological therapies.

By moving beyond a testing-focused approach, the guidance emphasizes comprehensive potency assurance through manufacturing process design, material controls, risk assessment, in-process monitoring and reliable analytical methods.

For CGT manufacturers, biotechnology companies and CDMOs, the recommendations highlight the importance of integrating potency considerations into every stage of product development and commercial manufacturing.

Companies should review their existing CMC strategies, strengthen potency-related analytical methods, establish appropriate acceptance criteria and maintain robust documentation to support regulatory submissions and ongoing product quality.

A proactive approach to potency assurance can help improve manufacturing consistency, strengthen product quality and support the development of safe and effective cellular and gene therapies.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports pharmaceutical, biotechnology and advanced therapy companies with:

  • FDA regulatory assessments for cellular and gene therapy products.
  • CGT potency assurance strategy development.
  • FDA potency guidance applicability reviews.
  • CMC regulatory documentation and gap assessments.
  • Potency assay development and qualification support.
  • Analytical method validation assessments.
  • Critical quality attribute (CQA) and critical process parameter (CPP) assessments.
  • Manufacturing process and quality risk assessments.
  • Stability and comparability assessment support.
  • IND and BLA regulatory documentation support.
  • Reference material and assay lifecycle management reviews.
  • Pharmaceutical quality system assessments.
  • Regulatory submission readiness assessments.
  • Global regulatory intelligence and lifecycle compliance support.

Our approach helps biotechnology companies, CGT manufacturers and pharmaceutical organizations identify regulatory gaps, strengthen CMC strategies and develop practical compliance approaches aligned with evolving FDA expectations.